Lung Therapeutics announced that it has raised $36 million in Series C financing to fund two projects, including a healthy volunteer Phase 1 clinical trial testing LTI-03, an experimental therapy for idiopathic pulmonary fibrosis (IPF). Currently approved therapies for IPF can slow disease progression, but cannot restore…
An exploratory Phase 2 study of Prometic‘s investigative oral therapy PBI-4050 in patients with idiopathic pulmonary fibrosis (IPF) showed “encouraging” results and no safety concerns, a study reports. Alone or in combination with Ofev (nintedanib), PBI-4050 was well-tolerated and showed…
As many as one in four people with idiopathic pulmonary fibrosis (IPF) may have the illness as a result of inhaling vapors, gas, dust, or fumes at work, according to an official statement by the American Thoracic Society (ATS) and the European Respiratory Society (ERS). Such occupational…
There is no direct pathway when it comes to nutrition intervention for pulmonary fibrosis (PF), but a recent study found that nearly one-third of idiopathic PF (IPF) patients were malnourished, which indicates the intrinsic value of ensuring a proper…
This week, the world lost a champion. On June 3, 2019, Kim Fredrickson, a stoic and heroic inspiration to so many people living with pulmonary fibrosis (PF), died after nearly four months in the intensive care unit at UCSF Medical Center, where she was awaiting a life-saving…
Plans for a Phase 2 clinical trial of brilaroxazine, the lead candidate by Reviva Pharmaceuticals to treat idiopathic pulmonary fibrosis (IPF), were the focus of a recent and successful meeting between company officials and the U.S. Food and Drug Administration (FDA), Reviva announced. During this pre-Investigational New Drug (IND) Application meeting, the regulatory…
The Pulmonary Fibrosis Foundations (PFF)’ Patient Registry is providing valuable data to support pulmonary fibrosis research, as evidenced by multiple presentations at the 2019 American Thoracic Society (ATS) conference, held May 17–22 in Dallas, Texas. The PFF Patient registry, launched in 2016, is a comprehensive collection of patient…
Patients with idiopathic pulmonary fibrosis (IPF) produce a large amount of abnormal airway immune cells lacking an iron receptor that plays an important role in defending the lungs against pollutants and microbes, a study shows. The missing iron receptor is strongly correlated with poor clinical outcomes for patients, and…
An international group of experts and advocates in idiopathic pulmonary fibrosis (IPF) and other interstitial lung diseases (ILDs) have joined to create the Open Source Imaging Consortium (OSIC), a not-for-profit effort to advance the diagnosis of these illnesses with the help of digital imaging and machine learning. According…
The first patient was dosed in a Phase 2b clinical trial investigating the safety and effectiveness of Respivant Biosciences’ inhalation therapy candidate RVT-1601 for idiopathic pulmonary fibrosis patients with persistent cough. Respivant Biosciences also has launched a new website — IPFcough.com — to increase awareness about the effects of cough…
Get regular updates to your inbox.
